Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
東瑞製葯向康方生物悉售創新藥物產品研發合資35%股權

2024-02-09T  
第九批國家組織藥品集採41種藥品採購成功 擬中選藥品平均降價58%

2023-11-07T  
《公司業績》東瑞製葯半年純利2.56億元人民幣升49.1% 派中期息1.5港仙

2023-08-28T  
東瑞製葯(02348.HK)合營高膽固醇血症新藥上市申請獲受理

2023-06-02T  
《公司業績》東瑞製葯(02348.HK)全年純利3.6億人幣按年持平 派末期息7.3港仙

2023-03-27T  
國家藥監局:將持續完善疫苗管理體制 加快新藥好藥上市

2023-01-06T  
東瑞製葯(02348.HK)附屬向康融東方提供1.05億人幣無抵押貸款

2022-10-25T  
《公司業績》東瑞製葯(02348.HK)中期純利1.72億人民幣增3% 派息1.5港仙

2022-08-28T  
《公司業績》東瑞製葯(02348.HK)全年純利3.58億人幣升33.6% 派末期息6.5港仙

2022-03-28T  
東瑞製葯(02348.HK)總裁變更

2022-02-16T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.